In addition to paying for insulin, individuals with T1D also face other health-related costs including doctors’ visits, supplies (including diabetes technologies), medications for comorbid conditions, and the loss of income and/or educational opportunity to attend to the multiple management needs of diabetes (20). This evidence concerns the gene INS and type 1 diabetes mellitus.